Pagniez, F.
Professeur
Publications
P312
ChemMedChem 2026, 21, e70338.
Bicyclic Lactams From Chiral Imines: Synthesis, Structural Optimization, and Biological Evaluation of Promising Antileishmanial Agents.
https://doi.org/10.1002/cmdc.70338
P302
Inorg. Chem., 2025, 64, 16192-16203.
Synthesis and Biological Evaluation of Itraconazole Derivatives: Design in an Old Scaffold.
https://doi.org/10.1021/acs.inorgchem.5c02730
P300
RSC Med. Chem. 2025, 16, 3746–3763.
Pharmacophore-guided optimization of the hit compound CTN1122 in the design of promising imidazo[1,2-a]pyrazine derivatives targeting the casein kinase 1 for antileishmanial therapy
https://doi.org/10.1039/D5MD00257E
P290
ChemMedChem. 2025, 20, e202400862.
Investigating the C2 modulation of the imidazo[1,2-a]pyrazine-based hit compound CTN1122: synthesis, in vitro antileishmanial activity, cytotoxicity and casein kinase 1 inhibition.
https://doi.org/10.1002/cmdc.202400862
P280
Chem. Biodiversity 2024, e202300563
Chemical Composition, Antifungal, Antioxidant, and Hemolytic Activities of Morrocan Thymus capitatus Essential Oil.
https://doi.org/10.1002/cbdv.202300563
P271
J. Med. Chem. 2023.
Discovery of new broad-spectrum anti-infectives for eukaryotic pathogens using boorganometallic chemistry.
https://doi.org/10.1021/acs.jmedchem.3c01333
P249
PLoS One 2022.
CRISPR-Cas9 approach confirms Calcineurin-responsive zinc finger 1 (Crz1) transcription factor as a promising therapeutic target in echinocandin-resistant Candida glabrata.
https://doi.org/10.1371/journal.pone.0265777
P246
Microorganisms. 2022, 10, 104.
Impact of TR34/L98H, TR46/Y121F/T289A and TR53 alterations in azole‐resistant Aspergillus fumigatus on sterol composition and modifications after In Vitro exposure to itraconazole and voriconazole.
https://doi.org/10.3390/microorganisms10010104
P234
Med. Chem. Res. 2021, 30, 152-162.
Antimicrobial and anti-leishmanial activities of extracts and some constituents from the leaves of Solanum chrysotrichum Schldl.
doi: 10.1007/s00044-020-02648-8
P231
Eur. J. Med. Chem. 2021, 210, 112956.
In vitro identification of imidazo[1,2-a]pyrazine-based antileishmanial agents and evaluation of L. major casein kinase 1 inhibition.
doi: 10.1016/j.ejmech.2020.112956
P223
Pharmaceuticals. 2020, 13, 186.
Optimization, Antifungal Activity, Selectivity, and CYP51 Binding of New 2-Aryl-3-azolyl-1-indolyl-propan-2-ols.
doi:10.3390/ph13080186
P212
Eur. J. Med. Chem. 2020, 189, 112082.
New Azole Antifungals with a Fused Triazinone Scaffold.
doi: 10.1016/j.ejmech.2020.112082
P208
J. Enzym. Inhib. Med. Chem. 2020, 35, 398-403.
Biological exploration of a novel 1,2,4-triazole-indole hybrid molecule as antifungal agent.
doi: 10.1080/14756366.2019.1705292
P146
Med. Mycol. 2016, 54, 764-775.
The amino acid substitution N136Y in Candida albicans sterol 14alpha-demethylase is involved in fluconazole resistance.
doi: 10.1093/mmy/myw023
P144
Eur. J. Pharm. Biopharm. 2016, 101, 137-144.
Econazole imprinted textiles with antifungal activity.
doi: 10.1016/j.ejpb.2016.02.003
P136
Eur. J. Med. Chem. 2015, 103, 381-395.
Synthesis, antileishmanial activity and cytotoxicity of 2,3-diaryl- and 2,3,8-trisubstituted imidazo[1,2-a]pyrazines.
doi: 10.1016/j.ejmech.2015.09.002
P134
J. Nanopharmaceutics Drug Delivery 2014, 2, 1-11.
Enhanced pulmonary administration of amphotericin B loaded in PEG-g-PLA nanoparticles: in vitro proof-of-concept and susceptibility against Candida spp. and Aspergillus spp.
P123
Int J. Antimicrob. Agents. 2013 Nov;42(5):410-5.
Deciphering azole resistance mechanisms with a focus on transcription factor-encoding genes TAC1, MRR1 and UPC2 in a set of fluconazole-resistant clinical isolates of Candida albicans.
P115
Phytochemistry Letters, 2013; 6(3):498-503.
Anti-AGEs and antiparasitic activity of an original prenylated isoflavonoid and flavanones isolated from Derris ferruginea.
P114
ACS Med. Chem. Lett., 2013, 4, 288-292.
Discovery of a novel broad-spectrum antifungal agent, derived from albaconazole.
Autres publications scientifiques
Brevets
B17.
Novel fused pyrimidone and triazinone derivatives containing bridged nitrogen, their process of preparation and their therapeutic uses as antifungal and/or antiparasitic agents.
PCT WO 2017/021178 A1, 9 février 2017.
B14.
Milieu, dispositif et procédé de test de la sensibilité d'un inoculum de champignons à un agent antifongique.
B9.
Antifungal and/or antiparasitic pharmaceutical composition and novel indole derivatives as active principle of such a composition.
Brevet US 2004067998 A1 publié le 8 avril 2004.
B8.
Antifungal and/or antiparasitic pharmaceutical composition and novel indole derivatives as active principle of such a composition.
Brevet CN 1473160A publié le 4 février 2004.
B7.
Procédé de détection de la sensibilité des levures aux antifongiques.
Brevet /FR 1 54 056 - A1 2003.
B6.
New azolyl-substituted indole derivatives and analogs, useful as antifungal and antiparasitic drugs effective e.g. against Candida albicans, Aspergillus fumigatus and Leishmania.
Brevet EP 1322638 publié le 2 juillet 2003.
B5.
Indole derivatives and their use as antifungal and/or antiparasitic agents.
Brevet CA 2 423 151 A1 publié le 21 mars 2003.
B2.
Antifungal and/or antiparasitic pharmaceutical composition and novel indole derivatives as active principle of such a composition.
Brevet PCT WO 02/24685 A1 déposé le 21 septembre 2001, publié le 28 mars 2002.
B1.
Composition pharmaceutique antifongique et/ou antiparasitaire et nouveaux dérivés de l'indole à titre de principes actifs d'une telle composition
Brevet FR 2 814 073 - A1 déposé le 21 septembre 2000, publié le 22 mars 2002.
Thèse
T07.
Evaluation et exploration des mécanismes d'action de nouveaux dérivés azolybenzylindoles antileishmaniens et antifongiques.
Nantes, 20 décembre 2001.